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Abstract
Introduction: This study aims to explore the relationship between the methylation of matrix metalloproteinase (MMP)-9 gene promoter 
region and diabetic nephropathy (DN) through the detection of the methylation level of MMP-9 gene promoter region in the peripheral 
blood of patients with DN in different periods and serum MMP-9 concentration. 
Material and methods: The methylation level of the MMP-9 gene promoter region was detected by methylation-specific polymerase chain 
reaction (MSP), and the content of MMP-9 in serum was determined by enzyme-linked immunosorbent assay (ELISA). 
Results: Results of the statistical analysis revealed that serum MMP-9 protein expression levels gradually increased in patients in the 
simple diabetic group, early diabetic nephropathy group, and clinical diabetic nephropathy group, compared with the control group, and 
the difference was statistically significant (P < 0.05). Compared with the control group, the methylation levels of MMP-9 gene promoter 
regions gradually decreased in patients in the simple diabetic group, early diabetic nephropathy group, and clinical diabetic nephropathy 
group, and the difference was statistically significant (P < 0.05). Furthermore, correlation analysis results indicated that the demethyla-
tion levels of the MMP-9 gene promoter region were positively correlated with serum protein levels, urinary albumin-to-creatinine ratio 
(UACR), urea, and creatinine, and was negatively correlated with GFR. 
Conclusions: The demethylation of the MMP-9 gene promoter region may be involved in the occurrence and development of diabetic 
nephropathy by regulating the expression of MMP-9 protein in serum. (Endokrynol Pol 2018; 69 (3): 269–275)
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Streszczenie
Wstęp: Celem pracy jest zbadanie zależności między metylacją regionu promotora genu metaloproteinazy macierzy zewnątrzkomórkowej 
typu 9 a nefropatią cukrzycową, poprzez wykrycie poziomu metylacji regionu promotora genu MMP-9 we krwi obwodowej pacjentów 
z nefropatią cukrzycową w różnych okresach i przy różnym stężeniu MMP-9 w surowicy krwi.
Materiał i metody: Poziom metylacji regionu promotora genu MMP-9 wykrywano za pomocą metylospecyficznej reakcji łańcuchowej 
polimerazy (methylation-specific polymerase chain reaction; MSP), natomiast zawartość MMP-9 w surowicy krwi była określana przy użyciu 
enzymatycznego testu immunoadsorpcyjnego (ELISA). 
Wyniki: Wyniki analizy statystycznej wykazały, że poziom ekspresji białka MMP-9 w surowicy krwi stopniowo wzrastał w grupie pa-
cjentów ze zwykłą cukrzycą, w grupie pacjentów z wczesną nefropatią cukrzycową oraz w grupie z kliniczną nefropatią cukrzycową 
w porównaniu z grupą kontrolną; różnica była statystycznie istotna (p < 0,05). W porównaniu z grupą kontrolną poziom metylacji 
regionów promotora genu MMP-9 stopniowo się zmniejszał w grupie pacjentów ze zwykłą cukrzycą, w grupie pacjentów z wczesną 
nefropatią cukrzycową oraz w grupie z kliniczną nefropatią cukrzycową; różnica była istotna statystycznie (p < 0,05). Ponadto, wyniki 
analizy korelacji wykazały, że poziomy demetylacji regionu promotora genu MMP-9 były dodatnio skorelowane ze stężeniem białek 
w surowicy krwi, ze wskaźnikiem albumina/kreatynina (urinary albumin to creatinine ratio; UACR), mocznikiem i kreatyniną oraz były 
ujemnie skorelowane ze wskaźnikiem GFR. 
Wnioski: Demetylacja regionu promotora genu MMP-9 może być zaangażowana w występowanie i rozwój nefropatii cukrzycowej 
poprzez regulację ekspresji białka MMP-9 w surowicy krwi. (Endokrynol Pol 2018; 69 (3): 269–275)
Słowa kluczowe: nefropatia cukrzycowa, metaloproteinaza macierzy zewnątrzkomórkowej typu 9, metylacja DNA
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Introduction
Diabetic nephropathy (DN) is a complex polygenic dis-
ease that involves many pathogenic genes, and is caused 
by the accumulated interactions of genetic and environ-
mental factors. It is of great significance for exploration of 
the pathogenesis, early diagnosis, prevention and delay 
occurrence and development of diabetic nephropathy, in 
order to improve the survival rate of diabetic patients and 
their quality of life. Matrix metalloproteinases (MMPs) 
are a group of zinc-dependent endopeptidases with 
common biochemical properties that are closely related 
to normal physiological and abnormal pathological 
changes of the kidney [1, 2]. Experiments in vitro have 
confirmed that high concentrations of glucose and ad-
vanced glycation end-products can affect the expression 
level of MMP-9 in renal parenchymal cells. It was found 
in the cultivation of lymphocytes that the mRNA and 
protein expression levels of MMP-9 were negatively cor-
related with the methylation status of the MMP-9 gene 
promoter [3]. Roach et al. [4] found in studies that the 
high expression of MMP-9 was associated with the low 
methylation level of the MMP-9 gene. The demethylation 
of the MMP-9 gene promoter may play an important 
role in the occurrence and development of tumours by 
enhancing the mRNA expression of MMP-9 and promot-
ing the secretion of MMP-9 protein.
At present, there are no related local or foreign 
reports that confirm the correlation between the meth-
ylation regulation of the MMP-9 gene promoter and 
DN, the difference in methylation status of the MMP-9 
gene promoter in patients in different DN stages, and 
the involvement of the MMP-9 gene promoter in the 
pathogenesis of DN. In order to further explore the role 
of the methylation status of the MMP-9 gene promoter 
in the pathogenesis of DN and the possible epigenetic 
regulation mechanism, patients with DN were selected 
as the research objects, their MMP-9 levels were de-
tected, and the methylation status of the MMP-9 gene 
promoter was detected by methylation-specific PCR. 
All these were carried out to elucidate the role of the 
methylation status of the MMP-9 gene promoter in the 
pathogenesis of DN, provide a new theoretical basis for 
the occurrence and development of DN, and provide 




The research objects were patients who continuously 
visited the Outpatient Endocrinology Department of 
the Affiliated Zhongshan Hospital of Dalian University 
from January 2015 to December 2015. These patients 
were diagnosed with impaired glucose regulation, 
simple type-2 diabetes mellitus, and early and clini-
cal stage of DN; and each included 30 cases. Patients 
who suffered from infection disease, high blood 
pressure, malignant tumour, coronary heart disease, 
heart failure, and obesity, and patients who were 
administrated with renal toxic drugs were excluded. 
Impaired glucose regulation and diabetes mellitus 
were diagnosed according to the criteria for diagnosis 
and classification of diabetes mellitus (WHO 1999). DN 
was divided into two categories by ACR, according to 
the Chinese type-2 diabetes prevention and treatment 
guidelines (2013 Edition): early diabetes (ACR: 2.5– 
–30.0 mg/mmol [male], 3.5–30.0 mg/mmol [female]) and 
clinical diabetes mellitus (ACR > 30.0 mg/mmol). All 
the patients with diabetic nephropathy simultaneously 
underwent a fundus examination to confirm whether 
they were combined with diabetic retinopathy. In ad-
dition, another 30 cases of healthy volunteers who took 
physical examinations at the same time were selected 
as the control group. All subjects were informed and 
provided signed informed consent. This study was ap-
proved by the Ethics Committee of the Hospital.
Research methods
Specimen collection
1. General data collection: Data collected from all sub-
jects included gender, age, duration of the disease, 
body mass index (BMI), fasting plasma glucose 
(FPG), glycosylated haemoglobin (HbA1c), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), 
triglyceride (TG), total cholesterol (TC), low density 
lipoprotein-cholesterol (LDL-C), blood urine nitro-
gen (BUN), creatinine (CR), urinary albumin/creati-
nine (UACR), and glomerular filtration rate (GFR).
2. Five millitres samples of elbow venous blood were 
collected from all subjects 8–12 hours after fasting. 
Two copies were collected per specimen. One copy 
was placed in a non-anticoagulant tube and shaken. 
The serum was separated within four hours and 
centrifuged at 3500 rpm for 10 minutes. Then, the 
serum in the upper layer was extracted and stored 
in a refrigerator at –80°C to detect the concentration 
of MMP-9 (within two months). The other copy was 
placed in an EDTA anticoagulation tube at –80°C for 
application (within two months).
Detection of methylation status of the MMP-9 gene
1. Specimen DNA extraction: The genomic DNA was 
extracted using an Ezup column blood genomic 
DNA extraction Kit (Shanghai Shenggong Biological 
Engineering Co., Ltd.). Operations were performed 
strictly in accordance with the operation instruc-
tions, based on the requirement.
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2. DNA modification by bisulphite transformation: 
The extracted leukocyte DNA was modified by 
bisulphite sodium, in strict accordance with the in-
structions of the kit, and the unmethylated cytosine 
(C) in the sequence was transformed into uracil (U). 
The modified DNA was purified and recovered ac-
cording to the specification of the reagent.
3. The design and synthesis of methylation of specific 
primers: According to the whole genomic sequence 
and the sequence of the promoter region of MMP-9, 
the CpG island of the MMP-9 gene promoter was 
searched using the DNA methylation research tool 
software “MethPrimer” (http://www.urogene.org/
methprimer/), and the primer was designed as fol-
lows. MMP-9 methylation primer: the sequence of 
the upstream primer was 5’- GAAGTTCGAAATT-
AGTTTGGTTAAC-3’, with a length of 25 bp; while 
the sequence of the downstream primers was 
5’-TCCCGAATAACTAATATTATAAACGTA-3’, with 
a length of 27 bp. MMP-9 non-methylated primer: 
the sequence of the upstream primer was 5’-AGTTT-
GAAATTAGTTTGGTTAATGT-3’, with a length of 25 
bp; while the sequence of the downstream primer 
was 5’-CCTCCCAAATAACTAATATTATAAACATA-3’, 
with a length was 29 bp. The above primers were 
synthesised by Shanghai Shenggong Biological 
Engineering Co., Ltd.
4. Methylation-specific PCR (MSP) amplification: 
Thermal cycling parameters were as follows: pre-
denaturation at 95°C for five minutes; denaturation 
at 94°C for 30 seconds, annealing at 56°C for 30 
seconds, extension at 72°C for 30 seconds, for a total 
of 35 cycles, and finally extended at 72°C for five 
minutes. PCR products were treated by 1% agarose 
gel electrophoresis, and the results were observed 
under a UV lamp.
Determination of MMP-9 concentration in serum  
samples by ELISA
MMP-9 serum levels were detected using a HUMAN 
MMP-9 ELISA KIT (Shanghai Langton Biological Tech-
nology Co., Ltd.), and experimental operations were 
strictly performed according to kit instructions.
Statistical methods
All data were processed using SPSS 22.0 software, and 
measurement data were expressed as mean value ± 
standard deviation (X ± SD). One-way ANOVA was 
performed for comparison among groups, and q-test 
(SNK) was used for pairwise comparisons. Count data 
were analysed by X2-test. The correlation between 
parameters was analysed by Spearman’s relativity 
method. P < 0.05 was considered statistically significant.
Results
Comparison of general conditions and  
biochemical indicators
The general conditions and biochemical indicators of 
the research objects in each group were compared. 
Results revealed that the difference in gender, age, BMI, 
SBP, DBP, TG, TC, and LDL-C among the five groups 
was not statistically significant (P > 0.05). The duration 
of the disease gradually increased with the aggravation 
of the disease. The duration was longer in the HbA1c 
DN group than in the simple diabetes group, and there 
was a difference between the DN group at clinical stage 
and the early DN group. However, the duration was 
shorter in the former than that in the early DN group. 
Furthermore, FPG in the diabetic nephropathy group 
was higher than in the diabetic group. This was higher 
in the diabetic nephropathy group at the clinical stage 
than in the early DN group. Regarding BUN and Cr, 
these were significantly higher in the DN group at clini-
cal stage than in the simple diabetes group and early 
diabetes group. In addition, the UACR in the DN group 
was significantly higher than in the diabetic group. This 
was significantly higher in the DN group at the clinical 
stage than in the early DN group. Compared with the 
simple diabetes group, the GFR of early DN slightly 
decreased, and this significantly decreased in the DN 
group at the clinical stage (Table I).
Analysis results of the CpG gene MMP-9 island
The blue part in Figure 1 was the CpG island, which 
has a total length of 110 bp (367–476).
Statistical analysis of methylation status in the 
promoter region of the MMP-9 gene
1. Agarose gel electrophoresis results: After MSP am-
plification, a 108-bp band could be found in some 
specimens (Fig. 2). If the target bands appear in 
the specimens amplified both by methylated prim-
ers and non-methylated primers, the specimens 
were determined as semi-methylation status. If 
the target band only appeared in specimens ampli-
fied by methylated primers, the specimens were 
determined as methylation status, i.e. methyla-
tion positive. If the target band only appeared in 
specimens amplified by non-methylation primers, 
the specimens were determined as unmethylation 
state, i.e. methylation negative. The experiment was 
repeated three times.
2. Statistics of the methylation status of MMP-9 gene 
promoter: The results indicate (Table II) that, com-
pared with the control group, the positive rate of 













MMP-9 promoter methylation and diabetic nephropathy Xiao-Hui Yang et al.
group slightly decreased. However, the difference 
was not significant, and there was no statistical 
significance (P > 0.05). Compared with the control 
group, the positive rates of methylation in the dia-
betes mellitus group, early DN group, and clinical 
DN group were significantly decreased, and the 
difference was statistically significant (P < 0.05). 
Compared with the diabetes mellitus group, the 
positive rates of methylation in the early DN group 
and clinical DN group significantly decreased, and 
the difference was statistically significant (P < 0.05). 
Compared with the early DN group, the positive 
rate of methylation in the clinical DN group signifi-
cantly decreased, and the difference was statistically 
significant (P < 0.05).
Table I. Comparison of each group’s general conditions (X ± S)
Tabela I. Porównanie ogólnej kondycji pacjentów w obu grupach (± S)
Variate Group A Group B Group C Group D Group E F/x2 P
Sex (male/female) 13/17 16/14 16/14 16/14 16/14 0.96 0.92
Age (years) 60.37 ± 8.42 61.43 ± 8.63 62.33 ± 6.94 62.67 ± 6.96 63.10 ± 7.05 0.55 0.66
BMI [kg/m2] 24.10 ± 2.63 24.36 ± 2.80 23.77 ± 2.10 23.91 ± 2.48 24.86 ± 2.66 0.86 0.49
SBP [mm Hg] 130.00 ± 7.66 130.83 ± 7.20 132.07 ± 7.06 133.23 ± 7.84 135.17 ± 6.63 2.339 0.58
DBP [mm Hg] 79.20 ± 8.04 81.33 ± 6.69 80.17 ± 7.82 80.17 ± 7.08 83.67 ± 6.29 1.7 0.15
TG [mmol/L] 1.36 ± 0.69 1.46 ± 0.46 1.29 ± 0.42 1.57 ± 0.66 1.47 ± 0.47 1.15 0.34
TC [mmol/L] 4.76 ± 0.71 4.80 ± 0.71 4.59 ± 0.60 4.75 ± 1.34 5.19 ± 0.90 1.91 0.11
LDL-C [mmol/L] 2.81 ± 0.64 2.92 ± 0.82 2.74 ± 0.55 2.92 ± 0.93 3.22 ± 1.01 1.5 0.2
Disease course (years) 0.0 ± 0.0 0.86 ± 0.58 5.96 ± 5.89*# 11.13 ± 5.76*# 12.37 ± 6.56*# 43.63 < 0.05
HbA1c (%) 5.58 ± 0.25 6.05 ± 0.65 8.12 ± 2.26
*# 10.02 ± 2.73*# 9.68 ± 2.60*# 31.37 < 0.05
FPG [mmol/L] 4.65 ± 0.62 4.89 ± 0.58 8.49 ± 3.55*# 9.72 ± 2.67*# 10.72 ± 3.64*# 27.31 < 0.05
BUN [mmol/L] 5.11 ± 1.10 5.51 ± 1.41 5.50 ± 1.28 6.58 ± 2.02 8.09 ± 4.29*# 8.03 < 0.05
Cr [μmol/l] 57.41 ± 9.53 58.12 ± 10.24 63.83 ± 12.29 65.97 ± 17.80 77.77 ± 32.93*# 5.78 < 0.05
UACR [mg/mmol] 0.26 ± 0.24 0.84 ± 0.91 0.44 ± 0.53 11.25 ± 7.55*# 73.57 ± 28.57*# 173.6 < 0.05
GFR 
[ml/min*1.73/m2]
111.97 ± 17.89 114.04 ± 13.94 118.32 ± 18.65 100.06 ± 20.34 85.55 ± 40.27*# 9.14 < 0.05
P value was corrected for Bonferroni correction; *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C;  
P < 0.05, compared with group D
Figure 1. The blue part is the CpG island, which has a total length 
of 110 bp (367–476)
Rycina 1. Część zaznaczona kolorem niebieskim była wyspą CpG, 
o łącznej długości 110 pz (367–476)
Table II. Statistical analysis of methylation status in the 
promoter region of the MMP-9 gene
Tabela II. Analiza statystyczna statusu metylacji w regionie 
promotora genu MMP-9
Group n Positive Positive rate (%)
Group A 30 28 93.33
Group B 30 27 90
Group C 30 14 46.67#
Group D 30 7 23.33#D
Group E 30 2 6.67#D
#P < 0.05,compared with group A; DP < 0.05,compared with group C;  
P < 0.05, compared with group D
Figure 2. Agarose gel electrophoresis results: After MSP 
amplification, a 108-bp band could be found in some specimens
Rycina 2. Wyniki elektroforezy w żelu agarozowym: po 
amplifikacji MSP, w niektórych próbkach znaleziono fragment 
o długości 108 pz
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Detection results of serum MMP-9 levels
Detection results of MMP-9 concentration levels in 
each group were compared, and these results revealed 
that concentrations in the impaired glucose regulation 
group were not significantly changed compared with 
the control group (P > 0.05). However, concentrations 
in the diabetes mellitus group, DN group and clinical 
DN group significantly increased (P < 0.05). Compared 
with the diabetes mellitus group, concentrations in the 
early DN group, and clinical DN group significantly 
increased, and the difference was statistically significant 
(P < 0.05). In addition, the concentration in the clinical 
DN group was significantly increased compared with 
that in the early DN group, and the difference was 
statistically significant (P < 0.05) (Table III).
The relationship between the serum expression of 
MMP-9 and the positive rate of methylation in 
the promoter region of the MMP-9 gene
The correlation between the serum expression of MMP-9 
and the positive rate of methylation in each group was 
statistically analysed. Results revealed that the expres-
sion level of MMP-9 in serum was negatively correlated 
with the methylation level of the MMP-9 gene promoter 
region. The analysis results are shown in Figure 3.
The correlation analysis of the methylation level 
of the MMP-9 gene promoter and other variables
Spearman’s correlation analysis was performed between 
the demethylation level of the MMP-9 gene promoter and 
age, BMI, duration of diabetes mellitus, fasting plasma 
glucose (FPG), HbA1c, BUN, Cr, UACR, GFR, and serum 
concentrations of MMP-9 in research objects. Results 
revealed that the demethylation of the MMP-9 promoter 
was positively correlated with the serum concentration 
MMP-9, the duration, FPG, HbA1c, BUN, Cr, and UACR, 
and was negatively correlated to GFR (Table IV).
Discussion
DN is the most common microvascular complication 
of diabetes mellitus, and it is also the most common 
cause of ESRD [5]. However, its pathogenesis remains 
unclear. Genetic susceptibility is an important factor in 
the occurrence of DN [6], while environmental factors 
may be involved in the occurrence and development 
of DN by affecting the changes of epigenetic modifica-
tions [7, 8]. DNA methylation modification is one of the 
most extensively and thoroughly studied epigenetic 
mechanisms at present. Sapienza C et al. [9] determined 
the methylation level in DNA extracted from saliva in 
end-stage DN patients and diabetic patients with no 
renal complications. These results revealed that there 
was a significant difference in at least two CpG sites 
Figure 3. The results of analysis of the relationship between the 
serum expression of MMP-9 and the positive rate of methylation 
in the promoter region of the MMP-9 gene
Rycina 3. Wyniki analizy zależności między ekspresją MMP-9 
w surowicy krwi a dodatnim tempem metylacji w regionie 
promotora genu MMP-9
Table III. Detection results of serum MMP-9 levels in each group
Tabela III. Wyniki wykrywania poziomu MMP-9 w surowicy 
krwi pacjentów z każdej z grup
Group MMP-9 [ng/mL]
Group A 100.87 ± 4.88
Group B 101.93 ± 4.00
Group C 132.67 ± 4.82#
Group D 212.03 ± 5.75#
Group E 246.27 ± 5.02#D
#P < 0.05, compared with group A; P < 0.05, compared with group C;  
DP < 0.05, compared with group D
Table IV. The correlation analysis of the methylation level of 
the MMP-9 gene promoter and other variables
Tabela IV. Analiza korelacji poziomu metylacji promotora 
genu MMP-9 i innych zmiennych
Variate Coefficient of association rs P value
Age 0.153 0.06
BMI 0.053 0.52
Disease course 0.678* < 0.05
FPG 0.568* < 0.05
HbA1c 0.571* < 0.05
BUN 0.231* < 0.05
Cr 0.186* < 0.05
UACR 0.670* < 0.05




*when the confidence (double side) is 0.05, the correlation is significant
in the two groups of DNAs. This suggests that DNA 
methylation plays an important role in the pathogenesis 
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The role of MMPs in the pathogenesis of diabetes is 
complex. The study of diabetic mice induced by strep-
tozocin revealed that the decrease in expression levels 
and activities of MMP-9 and MMP-2 contributed to the 
accumulation of the renal mesangial matrix [10]. The 
present experimental results revealed that the serum 
MMP-9 protein expression levels in the simple diabetes 
group, early DN group, and clinical DN group were 
higher than in the normal control group. Serum MMP-9 
protein expression level in the early DN group and 
clinical DN group were higher than in the simple DM 
group. The MMP-9 expression level in the clinical DN 
group was higher than in the early DN group. This was 
consistent with the conclusions on the research on DN 
carried out by Tashiro K et al. [11], in which the levels 
of MMP-9 in many albuminuria diabetic patients were 
significantly higher than that in the normal control 
group, and this increasing degree was consistent with 
the clinical staging of the disease. In DN patients, the 
expression of MMP-9 protein and its catalytic activity 
increased. However, DN can be assuaged through the 
suppression of the expression of MMP-9 in kidneys via 
genetic effects or drug intervention [12]. All these results 
suggest that MMP-9 may be involved in the occurrence 
and development of DN.
Experimental results of the MSP analysis in the 
present study indicate that with the extension of DN 
duration, the positive rate of methylation significantly 
decreased (P > 0.05). Furthermore, Spearman’s correla-
tion analysis revealed that the correlation coefficient rs 
between the serum MMP-9 concentrations and its dem-
ethylation level was 0.736 (P < 0.05), suggesting that the 
demethylation level of the MMP-9 promoter region was 
positively related to its serum concentration. That is to 
say, the methylation of the MMP-9 promoter in DN was 
negatively correlated with serum concentration. Similar 
conditions were also found in other diseases. Campos et 
al. found that [13] in periapicalitis, the decreasing extent 
of methylation of the MMP-9 promoter was consistent 
with the increasing extent of transcription of MMP-9 
mRNA. Roach et al. found that [4] the high expression 
of MMP-9 was associated with the low methylation 
level of the MMP-9 gene. In patients with non-small 
cell lung cancer, the average methylation density of the 
MMP-9 promoter was significantly lower than that in 
the healthy group, which revealed a significantly lower 
methylation status [14]. The experiment in vitro con-
firmed that the methylation status of the MMP-9 gene 
promoter played an inhibition role in transcriptional 
activity. It was observed in lymphocyte cultivation that 
the methylation status of the MMP-9 gene promoter was 
negatively correlated with MMP-9 mRNA and protein 
expression levels. When lymphocytes were treated by 
the DNA methylation inhibitor, the methylation status 
of the MMP-9 gene promoter could be reduced, and 
the mRNA and protein expression of MMP-9 could be 
promoted [15].
In the present experiment, the positive rate of 
methylation of the MMP-9 promoter in the impaired 
glucose regulation group was slightly lower than that 
in the control group. However, the difference was not 
significant (P > 0.05). This may be related to the dura-
tion and severity of the disease, the duration of patients 
in the impaired glucose regulation group was relatively 
short, the regulating ability and metabolic function 
were acceptable, and the factors affecting the activity 
of MMP-9 transcription may be fever. Spearman’s cor-
relation analysis results revealed that the demethylation 
of the MMP-9 promoter region was positively related 
to the duration of the disease, fasting plasma glucose 
(FPG), and HbA1c, which suggests that longer disease 
duration and poor blood glucose control resulted in 
a greater impact of MMP-9 transcriptional levels and 
a greater expression of MMP-9, thus affecting the pro-
gression of DN. Roach [9] et al. found in the study on the 
cartilage of osteoarthritis that the expression of MMP-9 
increased compared with the normal control group, 
and this was related to the low methylation level of the 
MMP-9 gene, which was consistent with the results of 
the present experiment.
In the present experiment, we attempted to elimi-
nate the controllable factors for comparative analysis. 
In fact, there are many deficiencies in this study: the 
sample numbers were fewer, and DN is usually diag-
nosed by renal biopsy, However, it is difficult to practice 
in clinical trials. The experiments in vivo were affected 
by factors such as emotion, real-time blood glucose 
variations, and other. Furthermore, the MMP-9 mRNA 
levels were not detected, and no sequencing analysis 
was performed after MSP amplification. In future re-
search, the methylation status of local kidney tissue can 
be selected to compare with that of the peripheral blood 
in animal experiments, the in vitro cell experiment 
can also be performed to exclude interference factors, 
and the sample size can be increased in order to study 
and validate the aberrant methylation of MMP-9 gene 
promoter in DN, as well as to elaborate the role of the 
methylation of the MMP-9 gene promoter in the occur-
rence and development of DN more comprehensively, 
so as to provide a new basis for the early prevention 
and treatment of DN.
Conclusions
The demethylation of the MMP-9 gene promoter may be 
involved in the occurrence and development of DN by 
regulating the expression of MMP-9 protein in serum.
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